These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35839452)

  • 1. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
    Elsawy M; Chavez JC; Avivi I; Larouche JF; Wannesson L; Cwynarski K; Osman K; Davison K; Rudzki JD; Dahiya S; Dorritie K; Jaglowski S; Radford J; Morschhauser F; Cunningham D; Martin Garcia-Sancho A; Tzachanis D; Ulrickson ML; Karmali R; Kekre N; Thieblemont C; Enblad G; Dreger P; Malladi R; Joshi N; Wang WJ; Solem CT; Snider JT; Cheng P; To C; Kersten MJ
    Blood; 2022 Nov; 140(21):2248-2260. PubMed ID: 35839452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
    Westin JR; Locke FL; Dickinson M; Ghobadi A; Elsawy M; van Meerten T; Miklos DB; Ulrickson ML; Perales MA; Farooq U; Wannesson L; Leslie L; Kersten MJ; Jacobson CA; Pagel JM; Wulf G; Johnston P; Rapoport AP; Du L; Vardhanabhuti S; Filosto S; Shah J; Snider JT; Cheng P; To C; Oluwole OO; Sureda A
    Clin Cancer Res; 2023 May; 29(10):1894-1905. PubMed ID: 36999993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.
    Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
    Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
    Westin JR; Oluwole OO; Kersten MJ; Miklos DB; Perales MA; Ghobadi A; Rapoport AP; Sureda A; Jacobson CA; Farooq U; van Meerten T; Ulrickson M; Elsawy M; Leslie LA; Chaganti S; Dickinson M; Dorritie K; Reagan PM; McGuirk J; Song KW; Riedell PA; Minnema MC; Yang Y; Vardhanabhuti S; Filosto S; Cheng P; Shahani SA; Schupp M; To C; Locke FL; ;
    N Engl J Med; 2023 Jul; 389(2):148-157. PubMed ID: 37272527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
    Nastoupil LJ; Jain MD; Feng L; Spiegel JY; Ghobadi A; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Sehgal AR; Goy A; Hill BT; Vu K; Andreadis C; Munoz J; Westin J; Chavez JC; Cashen A; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Locke FL
    J Clin Oncol; 2020 Sep; 38(27):3119-3128. PubMed ID: 32401634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.
    Perales MA; Kuruvilla J; Snider JT; Vadgama S; Blissett R; El-Moustaid F; Smith NJ; Patel AR; Johnston PB
    Transplant Cell Ther; 2022 Nov; 28(11):750.e1-750.e6. PubMed ID: 35970302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
    Kambhampati S; Saumoy M; Schneider Y; Serrao S; Solaimani P; Budde LE; Mei MG; Popplewell LL; Siddiqi T; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
    Blood; 2022 Nov; 140(19):2024-2036. PubMed ID: 35914220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
    Locke FL; Miklos DB; Jacobson CA; Perales MA; Kersten MJ; Oluwole OO; Ghobadi A; Rapoport AP; McGuirk J; Pagel JM; Muñoz J; Farooq U; van Meerten T; Reagan PM; Sureda A; Flinn IW; Vandenberghe P; Song KW; Dickinson M; Minnema MC; Riedell PA; Leslie LA; Chaganti S; Yang Y; Filosto S; Shah J; Schupp M; To C; Cheng P; Gordon LI; Westin JR;
    N Engl J Med; 2022 Feb; 386(7):640-654. PubMed ID: 34891224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
    Locke FL; Oluwole OO; Kuruvilla J; Thieblemont C; Morschhauser F; Salles G; Rowe SP; Vardhanabhuti S; Winters J; Filosto S; To C; Cheng P; Schupp M; Korn R; Kersten MJ
    Blood; 2024 Jun; 143(24):2464-2473. PubMed ID: 38557775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
    Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
    Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
    Patrick DL; Powers A; Jun MP; Kim Y; Garcia J; Dehner C; Maloney DG
    Blood Adv; 2021 Apr; 5(8):2245-2255. PubMed ID: 33904895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
    Ghione P; Palomba ML; Patel AR; Bobillo S; Deighton K; Jacobson CA; Nahas M; Hatswell AJ; Jung AS; Kanters S; Snider JT; Neelapu SS; Ribeiro MT; Brookhart MA; Ghesquieres H; Radford J; Gribben JG
    Blood; 2022 Aug; 140(8):851-860. PubMed ID: 35679476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.
    Loftager ASL; Danø A; Eklund O; Vadgama S; Hedlof Kanje V; Munk E
    J Med Econ; 2023; 26(1):1303-1317. PubMed ID: 37725082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N
    Transplant Cell Ther; 2024 Jun; 30(6):584.e1-584.e13. PubMed ID: 38281590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
    Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
    J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
    Mian A; Wei W; Winter AM; Khouri J; Jagadeesh D; Anwer F; Gerds AT; Dean RM; Sobecks R; Pohlman B; Hamilton BK; Majhail NS; Hill BT
    Leuk Lymphoma; 2021 Jun; 62(6):1344-1352. PubMed ID: 33375873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.
    Locke FL; Filosto S; Chou J; Vardhanabhuti S; Perbost R; Dreger P; Hill BT; Lee C; Zinzani PL; Kröger N; López-Guillermo A; Greinix H; Zhang W; Tiwari G; Budka J; Marincola FM; To C; Mattie M; Schupp M; Cheng P; Bot A; Shen R; Bedognetti D; Miao H; Galon J
    Nat Med; 2024 Feb; 30(2):507-518. PubMed ID: 38233586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
    Jacobson CA; Locke FL; Ma L; Asubonteng J; Hu ZH; Siddiqi T; Ahmed S; Ghobadi A; Miklos DB; Lin Y; Perales MA; Lunning MA; Herr MM; Hill BT; Ganguly S; Dong H; Nikiforow S; Hooper M; Kawashima J; Xu H; Pasquini MC
    Transplant Cell Ther; 2022 Sep; 28(9):581.e1-581.e8. PubMed ID: 35609867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.